Visit us at the Association for Molecular Pathology Annual Meeting 2018 in San Antonio!
Stop by our booth in the exhibit hall the AMP meeting in November!
Also check out our scientific posters with topics on fine needle aspirate fixation & analysis and plasma preparation parameters for circulating DNA workflows:
Abstract Title: Influence of Centrifugation Conditions for Plasma Processing on ccfDNA Yield
Poster Number: TT007
Abstract Number: 15967
Category: Technical Topics
Circulating cell-free DNA (ccfDNA) in blood has become widely accepted for biomarker analysis in academic and clinical research and beyond. Considering the usual low sample input and required high sensitivity for target detection optimal outcomes require validation and control of the entire workflow. The PAXgene Blood ccfDNA System (RUO) integrates preanalytical steps from sample collection to ccfDNA extraction for subsequent analysis by quantitative PCR (qPCR), digital PCR (ddPCR) and next-generation sequencing (NGS). Presented here is the influence of centrifugation conditions for plasma processing on ccfDNA yield and compatibility with primary tube handling on the QIAsymphony® SP instrument using the QIAsymphony PAXgene Blood ccfDNA Kit* and protocol.
Presentation: Saturday, November 3, 9:45am – 10:45am
Abstract Title: Evaluation of a Novel Formalin/Methanol-Free FNA Fixative for Study of Lung Cancer
Lung cancer remains a leading cause of cancer mortality worldwide. Identification of actionable mutations is a key strategy for guiding personalized care and highly dependent on nucleic acid quality. Currently, formalin and methanol based fixation methods for pathology samples are a rate-limiting step for tumor molecular analysis. STRATFix is an Innovate UK-funded collaborative project between QIAGEN and NHS pathology teams across the UK. A major aim was to compare PAXgene (a novel formalin/methanol-free fixative) to traditional fixation approaches and to evaluate performance in regards to preservation of cellular morphology and DNA/RNA which are now crucial for the molecular study of lung cancer.
Presentation: Friday, November 2, 2:30pm – 3:30pm